Utilizing AI based capabilities and real-world data sets
Concerto Health AI, the maker of a clinical insight generation platform has announced that it has collaborated with Pfizer, a biopharmaceutical company to progress its research in Precision Oncology. Pfizer will progress its research in Precision Oncology by utilizing Concerto Health’s eurekaHealth platform, Artificial intelligence (AI) models, and Real World Clinical Electronical Medical Record (EMR). Furthermore, a broad range of data obtained from the real world data sets of clinical practices participating in the American Society of Clinical Oncology’s CancerLinQ initiative and other practices across the USA will be utilized for the collaboration.
Jeff Elton, CEO of Concerto HealthAI stated, “This collaboration aims to find and help patients who may benefit from new therapeutic combinations. We are using our definitive real-world data, AI-enabled abstraction, data science expertise, and strength in outcomes research to identify new and more precise treatment options; refine study designs, and speed up the completion times for various outcomes studies.”
Accelerating the pace of inventive insights for therapeutics
With the integration of Concerto HealthAI’s real-world data and advanced AI capabilities, there will be an acceleration in the pace for inventive insights for Pfizer’s investigational therapies and commercialized therapeutics used in the treatment of solid tumours and hematologic malignancies.
Romesh Wadhwani, Executive Chairman of Concerto HealthAI stated, “The talented individuals of Pfizer and Concerto HealthAI working together, with our eurekaHealth AI platform and real-world data, allows us to go much faster when it comes to finding and acting on meaningful insights in key cancer subpopulations.”
Improving patient outcomes through study designs
The collaboration will conduct unique synthetic control arm and future real-world data patient outcomes study designs for therapeutics. This relies on research in study designs based on real-world data that CancerLinQ, Concerto HealthAI, and others have initiated in collaboration with the U.S. Food and Drug Administration. The collaboration will be supervised by a joint steered committee of Concerto HealthAI and Pfizer. The first outcomes research and publications are expected in early 2020.
Chris Boshoff, Chief Development Officer, Oncology of Pfizer Global Product Development stated, “Pfizer believes real-world data have tremendous potential to inform how we develop and use medicines to improve patient outcomes. “We are pleased to work with Concerto HealthAI –– to accelerate insights and outcomes studies that may lead to a more comprehensive understanding of patients’ experience with our medicines.”